Gabriel Scheubeck

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Venues

Annals of hematology

Leukemia

This page only lists publications with an associated author ORCID identifier.

Publications

Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling, null null
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of hematology 103 (7) (2024)
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling, null null
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of hematology 103 (7) (2024)
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling, null null
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of hematology (2024)
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling, null null
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of hematology 103 (7) (2024)
Gabriel Scheubeck, Martin Hoffmann, Vindi Jurinovic, Luca Fischer, Michael Unterhalt, Christian Schmidt, Hans-Peter Böck, Ulrich Dührsen, Joachim Kaesberger, Stephan Kremers, Hans-Walter Lindemann, Luisa Mantovani, Wolfgang Hiddemann, Eva Hoster, Martin Dreyling, null null
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group. Annals of hematology 103 (7) (2024)
Gabriel Scheubeck, Linmiao Jiang, Olivier Hermine, Hanneke C Kluin-Nelemans, Christian Schmidt, Michael Unterhalt, Andreas Rosenwald, Wolfram Klapper, Andrea Evangelista, Marco Ladetto, Mats Jerkeman, Simone Ferrero, Martin Dreyling, Eva Hoster
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia (2023)

Gabriel Scheubeck.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Gabriel Scheubeck